Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY – Free Report) – Investment analysts at Erste Group Bank upped their FY2026 earnings per share estimates for shares of Sandoz Group in a research note issued to investors on Friday, September 18th. Erste Group Bank analyst H. Engel now anticipates that the company will earn $4.20 per share for the year, up from their previous estimate of $4.13. Erste Group Bank has a “Strong-Buy” rating on the stock. The consensus estimate for Sandoz Group’s current full-year earnings is $4.14 per share. Erste Group Bank also issued estimates for Sandoz Group’s FY2027 earnings at $4.60 EPS.
Sandoz Group Price Performance
OTCMKTS:SDZNY opened at $86.43 on Tuesday. The business’s 50-day moving average is $84.71 and its two-hundred day moving average is $83.45. Sandoz Group has a 12 month low of $55.42 and a 12 month high of $94.15. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.18 and a quick ratio of 0.77.
Sandoz Group Company Profile
Sandoz Group AG is a Switzerland-based pharmaceutical company focused on developing, manufacturing and supplying generic and biosimilar medicines. Its portfolio includes products across areas such as anti-infectives, immunology, oncology, ophthalmology, respiratory care and cardiovascular medicine, as well as injectable and specialty pharmaceuticals.
The company traces its origins to Sandoz, founded in Basel in 1886, and became an independent business through its separation from Novartis in 2023.
Featured Articles
- Five stocks we like better than Sandoz Group
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
